-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA CONFIRMS SEASTAR MEDICAL HAS FULFILLED THE POST-APPROVAL STUDY REQUIREMENTS FOR QUELIMMUNE® FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY (AKI) IN PEDIATRIC PATIENTS

Reuters·11/03/2026 13:23:14